Compare Global X Lithium & Battery Tech ETF (LIT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Tango Therapeutics Inc. — how do they compare? Global X Lithium & Battery Tech ETF trades at $64.94 (market cap $1.45B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 2.6× Global X Lithium & Battery Tech ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 57 Days and Tango Therapeutics Inc. for 0 Days on average.
| LIT | TNGX | |
|---|---|---|
Market Cap | $1.45B | $3.74B |
Volume | 204,733 | 3,438,781 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $32.90 |
52-Week Low | $56.39 | $7.50 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $67.65, down 1.05% with bearish technical signals from moving averages and oscillators. The ETF faces headwinds from volatile lithium prices and oversupply concerns, though long-term prospects remain supported by EV adoption trends. Recent news highlights significant short interest reduction and China's ambitious 30% EV fleet target by 2030.
Outlook is cautious near-term due to technical weakness and commodity volatility, but structural EV growth offers recovery potential. Risks include lithium price swings and geopolitical trade tensions, while institutional sentiment shows mixed signals with recent short covering.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
